HAVANA, Cuba, Dec 14 (ACN) The encouraging results of the Phase II-III clinical trial of the Cuban product NeuroEpo in patients with mild/moderate Alzheimer's disease, was one of the highlights of this week's meeting of the first secretary of the Central Committee of the Communist Party and president of the country, Miguel Diaz-Canel Bermudez, with scientists and experts from the Ministry of Public Health.
The result of the Center for Molecular Immunology (CIM) in collaboration with other BioCubaFarma institutions is a nasal formulation of recombinant EPO with low content of sialic acid, an isoform of similar composition to the natural EPO produced in the central nervous system, explained the lecturer on the subject, MSc Leslie Perez Ruiz.
According to her, the II-III clinical trial on the intranasal administration of the product showed that treatment with NeuroEPO for 48 weeks was safe and well tolerated -there were no serious adverse events-; most of the patients showed a reduction in the progression of cognitive deterioration and also improved secondary variables.
She also reported an improvement in cerebral perfusion in the parieto-temporal region, and that 72 % of the patients treated stabilized the global values of the electroencephalogram (EEG), among other results.
At the same time, the principal investigator of the clinical trial, Dr. Saily Sosa Perez, pointed out that we are in the presence of an achievement of Cuban science, and that there are only six drugs in the world to relieve the effects of the disease, and all of them are extremely expensive (treatment for one year can exceed 80,000 dollars). NeuroEpo, she added, will give us sovereignty, independence, to care for our patients and also for other patients in the world.
NeuroEpo, Sosa Perez concluded, are drops of hope. It will make it possible to make the path of those who undertake the one-way journey of Alzheimer's disease more dignified.
Nos reservamos el derecho de no publicar los comentario que incumplan con las normas de este sitio